The Developmental Research Program (DRP) will fund small investigator-initiated projects with direct cost budgets of between $50,000-75,000. We are guaranteeing $200,000 per year for the DRP. Federal SPORE funds will make up $75,000 in the first year, with possible increases in subsequent years depending upon the availability of funds. Institutional commitment from the Dana-Farber Cancer Institute will provide $125,000 per year. Every effort to add additional philanthropic dollars to this amount will be made. In the previous DF/HCC Breast SPORE Grants, DRPs led to publications, grants, and clinical trials. One of the DRP awards from the previous SPORE has formed the basis of a large portion of Project 3 of this grant. The process for soliciting applications, awarding grants, monitoring research progress, and making decisions about ongoing funding are described in this section. The DRP has a transparent peer-reviewed selection process that incorporates defined criteria for funding decisions. The committee that oversees the process and selects the award recipients is the Developmental Research Program and Career Development Awards (DRP/CDP) Governance and Review Committee. The DRP will initiate a broad call for proposals to ensure the most promising early-phase research projects to receive meritorious funding, and investigators at all DF/HCC member institutions will be eligible to submit proposals. The DF/HCC has a large and talented investigator group to provide a wealth of applications from which to choose, and we anticipate a robust response to each and every request for applications that is announced.
The Developmental Research Program awards will support early-phase research projects including: 1) enabling preliminary data;and 2) proof-of-concept experiments. The projects will all be focused on breast cancer research. This work should lead to more mature research projects with the goals of improving breast cancer prevention, detection, and treatment.
|Willis, Nicholas A; Panday, Arvind; Duffey, Erin E et al. (2018) Rad51 recruitment and exclusion of non-homologous end joining during homologous recombination at a Tus/Ter mammalian replication fork barrier. PLoS Genet 14:e1007486|
|Kabraji, Sheheryar; Ni, Jing; Lin, Nancy U et al. (2018) Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clin Cancer Res 24:1795-1804|
|Bian, X; Gao, J; Luo, F et al. (2018) PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 37:341-351|
|Bertrand, Kimberly A; Eliassen, A Heather; Hankinson, Susan E et al. (2018) Circulating Hormones and Mammographic Density in Premenopausal Women. Horm Cancer 9:117-127|
|Kensler, Kevin H; Beca, Francisco; Baker, Gabrielle M et al. (2018) Androgen receptor expression in normal breast tissue and subsequent breast cancer risk. NPJ Breast Cancer 4:33|
|Li, Ben B; Qian, Changli; Roberts, Thomas M et al. (2018) Targeted Profiling of RNA Translation. Curr Protoc Mol Biol :e71|
|Li, Ben B; Qian, Changli; Gameiro, Paulo A et al. (2018) Targeted profiling of RNA translation reveals mTOR-4EBP1/2-independent translation regulation of mRNAs encoding ribosomal proteins. Proc Natl Acad Sci U S A 115:E9325-E9332|
|Guerriero, Jennifer L (2018) Macrophages: The Road Less Traveled, Changing Anticancer Therapy. Trends Mol Med 24:472-489|
|Kuang, Yanan; Siddiqui, Bilal; Hu, Jiani et al. (2018) Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer 4:22|
|Liu, Hui; Murphy, Charles J; Karreth, Florian A et al. (2018) Identifying and Targeting Sporadic Oncogenic Genetic Aberrations in Mouse Models of Triple-Negative Breast Cancer. Cancer Discov 8:354-369|
Showing the most recent 10 out of 66 publications